Traders should monitor whether 2026 revenue recovers beyond the guided range, as current outlook reflects near-term headwinds. Margin expansion and cost control are positives, but dependency on large customers creates execution risk. The ERP implementation and late-stage pipeline commercialization could be catalysts post-2026.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 16 $4.37entry
- T+1 · 8mo ago −0.23%α −0.50% · $4.36
- T+5 · 8mo ago −7.32%α −5.28% · $4.05
- T+20 · 7mo ago +18.99%α +15.21% · $5.20
- T+60 · 5mo ago +27.46%α +16.98% · $5.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lifecore Biomedical reported strong financial results for the seven-month transition period ending December 31, 2025, with revenue up 20% YoY to $75.5 million and Adjusted EBITDA more than quintupling to $13.1 million. Margins expanded significantly due to cost discipline and operational improvements, though net loss remains substantial. The company guided for $120–125 million in revenue for 2026, a decline from pro forma 2025 revenue of $141.4 million, citing customer-specific headwinds.
Key Financial Metrics
Key Facts
- Revenue for the seven-month transition period (May 26–Dec 31, 2025) was $75.5 million, up 20% YoY from $63.0 million.
- Gross profit margin improved to 31.4% from 25.9% in the prior-year period, driven by operational initiatives.
- Operating expenses fell 31% YoY to $24.4 million, primarily due to lower SG&A.
- Adjusted EBITDA surged to $13.1 million from $2.6 million in the prior-year period.
- Net loss narrowed to $18.0 million from $30.6 million, but remains significant.
- Company guided 2026 revenue of $120–125 million, below 2025 pro forma revenue of $141.4 million, due to customer supply shifts and delayed launches.
- Free cash flow was $3.6 million despite a $4.7 million preferred stock fee payment.
- ERP system launched in January 2026 to support future efficiency.
Financial Impact
Revenue growth of 20% and Adjusted EBITDA up $10.5M YoY, but 2026 guidance implies a ~12% revenue decline from 2025 pro forma levels.
Risk Factors
- Revenue guidance for 2026 is below 2025 pro forma levels, indicating near-term contraction.
- High customer concentration: loss of key customers or delays in their programs significantly impact outlook.
- $50.2 million in Series A Convertible Preferred Stock redemption risk starting June 2026, which could strain liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256216 |
Track record
20 reports on LFCR
6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +45.27% at T+60 after the Mar 26, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
- Nov 13, 20263d ago DEFM14A Neutral 6/10 Entry $6.42 Now $6.42 +0.00% settles Nov 17
- Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
- Nov 4, 202612d ago 8-K Bearish 6/10 No price data
- Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
- Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
- Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
- Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
- Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers